Literature DB >> 8392361

Neurotransmitter receptors in Alzheimer disease.

J T Greenamyre1, W F Maragos.   

Abstract

Alzheimer disease (AD) is an exceedingly complex disorder in which numerous populations of neurons and neurotransmitter systems are damaged or destroyed. Effective treatment of the cognitive symptoms of AD does not exist, and new targets for therapeutic intervention are needed desperately. Traditionally, the neurotransmitter receptors have been the focus of new neuropsychopharmacological agents, so it seems reasonable to assess the status of these receptors in the AD brain. In this article, we review the quarter century of receptor research in AD. The limitations of receptor studies, in general, and the particular limitations of studying AD tissue are discussed. The cholinergic and glutamatergic systems have been implicated most directly in normal cognitive function, so the receptors for these neurotransmitters are emphasized in this review. We have attempted to point out the possible neurobiological roles and potential clinical significance of the various receptors in AD. Investigation of neurotransmitter receptors in AD provides a rational approach to the development of therapeutic and diagnostic strategies, and, at a minimum, should lead to a better understanding of the neurobiology of AD.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8392361

Source DB:  PubMed          Journal:  Cerebrovasc Brain Metab Rev        ISSN: 1040-8827


  7 in total

1.  Reduced cortical distribution volume of iodine-123 iomazenil in Alzheimer's disease as a measure of loss of synapses.

Authors:  A Soricelli; A Postiglione; M R Grivet-Fojaja; P P Mainenti; A Discepolo; A Varrone; M Salvatore; N A Lassen
Journal:  Eur J Nucl Med       Date:  1996-10

2.  In vivo measurement of glutamate loss is associated with synapse loss in a mouse model of tauopathy.

Authors:  Rachelle Crescenzi; Catherine DeBrosse; Ravi Prakash Reddy Nanga; Sanjana Reddy; Mohammed Haris; Hari Hariharan; Michiyo Iba; Virginia M Y Lee; John A Detre; Arijitt Borthakur; Ravinder Reddy
Journal:  Neuroimage       Date:  2014-07-05       Impact factor: 6.556

Review 3.  Brain electrical activity (quantitative EEG and bit-mapping neurocognitive CNV components), psychometrics and clinical findings in presenile subjects with initial mild cognitive decline or probable Alzheimer-type dementia.

Authors:  R Zappoli; A Versari; M Paganini; G Arnetoli; G C Muscas; P F Gangemi; M G Arneodo; D Poggiolini; F Zappoli; A Battaglia
Journal:  Ital J Neurol Sci       Date:  1995-09

4.  Regulation of the NMDA receptor-mediated synaptic response by acetylcholinesterase inhibitors and its impairment in an animal model of Alzheimer's disease.

Authors:  Guojun Chen; Paul Chen; Huibing Tan; Da Ma; Fei Dou; Jian Feng; Zhen Yan
Journal:  Neurobiol Aging       Date:  2007-06-06       Impact factor: 4.673

5.  5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases.

Authors:  G P Reynolds; S L Mason; A Meldrum; S De Keczer; H Parnes; R M Eglen; E H Wong
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

Review 6.  Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's Disease.

Authors:  Touqeer Ahmed; Saadia Zahid; Aamra Mahboob; Syeda Mehpara Farhat
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

7.  Glutamatergic and GABAergic metabolism in mouse brain under chronic nicotine exposure: implications for addiction.

Authors:  Mohammad Shameem; Anant Bahadur Patel
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.